Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).

Huadong to commercialize CAR-T from CARsgen in China for $30 million upfront

SOTIO Biotech

6/3/2023 | 3 minuty čtení

Vytisknout
Kopírovat odkaz

CARsgen and Huadong Medicine announced a collaboration for the commercialization of CARsgen's BCMA CAR-T product CT053 in mainland China. 

CT053, zevorcabtagene autoleucel (zevor-cel), is CARsgen's lead drug candidate and an autologous CAR T-cell product treating relapsed/refractory multiple myeloma. CT053 NDA was submitted to NMPA in October 2022.

PARTNERING

CARsgen and Huadong to collaborate on zevorcabtagene autoleucel in mainland China

With strong commercial capability and network, Huadong is granted the exclusive right to commercialize zevor-cel in mainland China. CARsgen will receive an upfront payment of $30 million) and is eligible to receive regulatory and commercial milestone payments up to $149 million. CARsgen will continue to be responsible for the development, regulatory approval, and manufacturing of CT053 in mainland China. 

Synaffix enters licensing agreements with Hummingbird and Amgen

Synaffix announced the signing of a licensing agreements with Amgen and Hummingbird Bioscience to develop next generation ADCs. Amgen will gain access to Synaffix’s antibody conjugation technology platforms comprising GlycoConnect, HydraSpace and select toxSYN linker-payloads for one ADC program with the option to exercise exclusive research and commercial licenses for an additional four programs at a later date. Synaffix will be eligible to receive up to $2 billion in payments spanning signature, program nomination and milestone payments, plus tiered royalties on commercial sales which are consistent with the financials of the recently signed licenses of Synaffix ADC technology platform. Amgen will be responsible for the research, development, manufacturing and commercialization of the ADCs and Synaffix will continue to be responsible for the manufacturing of components related to its technologies. Under the terms of the agreement with Hummingbird, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments, plus royalties on net sales. For the target licensed, Hummingbird Bio is granted rights to utilize Synaffix proprietary ADC technologies GlycoConnect and HydraSpace, in combination with select toxSYN linker-payloads.

Moderna and Cytomx announce strategic collaboration for mRNA-based therapeutics

Moderna, and CytomX Therapeutics announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody therapeutic platform. The research collaboration will leverage core scientific advances at Moderna and CytomX. CytomX's Probody technology enables proteins to be activated locally in diseased tissue, while remaining masked in systemic circulation. CytomX will receive an upfront payment of $35 million, including $5 million of pre-paid research funding. CytomX will continue to receive research funding and is eligible to receive up to approximately $1.2 billion in future development, regulatory, and commercial milestone payments. CytomX is also eligible to receive tiered royalties on global net sales of any products that are commercialized under the agreement. Moderna and CytomX will collaborate on discovery and pre-clinical development and Moderna will lead clinical development and commercialization of therapeutics resulting from the agreement. The agreement additionally provides Moderna with an option to participate in a future equity financing by CytomX subject to certain terms, conditions and regulatory requirements.

WuXi and GSK enter a license agreement on multiple novel bi- and multi-specific T cell engagers

WuXi Biologics announced a license agreement with GSK under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics’ proprietary technology platforms. GSK will be granted an exclusive global license for the research, development, manufacturing, and commercialization of a pre-clinical bispecific antibody that crosslinks tumor cells and T cells by targeting a tumor-associated antigen (TAA) on tumor cells and CD3 expression on T cells and up to three additional pre-clinical TCE antibodies currently at an earlier discovery stage. WuXi Biologics will receive a $40 million upfront payment and up to $1.46 billion in additional payments for research, development, regulatory and commercial milestones across the four TCE antibodies. WuXi Biologics is also eligible to receive tiered royalties on net sales.

Overview of transactions in oncology (values in m$)

Source

Partner

Product

Stage

Rights

Value

UF

MS

Hutchmed China

Takeda

License to small molecule VEGFR inhibitor fruquintinib approved in China for colorectal cancer

Market

Ex-CN

1 130

400

730

Clinigen  Group

Iovance Bio-therapeutics

License to Proleukin, a biological activating aldesleukin and native human IL-2 approved for renal cancer

Market

WW

259

207

52

CARsgen Therapeutics

Huadong Medicine

License to zevorcabtagene autoleucel, a BCMA-targeting CAR-T developed against multiple myeloma

Filed

CN

179

30

149

WuXi   Biologics

GSK

License to bispecific T cell engaging antibody and option to three additional multi-specific TCE antibodies for cancer

Precl

WW

1 540

40

1 500

Synaffix

Amgen

License to GlycoConnect, HydraSpace and toxSYN technologies to develop next generation ADC against cancer

Res

WW

2 000

NA

NA

Immunome

AbbVie

License to Human memory B cell platform to discover up to 10 targets and antibodies to treat cancer

Res

WW

1 270

70

1 200

CytomX Therapeutics

Moderna

License to Probody technology platform to develop mRNA-based conditionally activated therapies against cancer

Res

WW

1 235

35

1 200

Anima Biotech

AbbVie

License to mRNA discovery technology and phenotypic screening to develop three targets spanning oncology

Res

WW

580

42

540

Kronos Bio

Genentech

License to Small Molecule Microarray platform to discover molecules targeting cancer-driving TF targets

Res

WW

574

20

554

3T  Biosciences

Boehringer Ingelheim

License to 3T TRACE platform to identify most prevalent and immunogenic targets in solid tumors

Res

WW

NA

NA

268

Synaffix

Hummingbird Bioscience

License to GlycoConnect, HydraSpace and toxSYN technologies to develop next generation ADC against cancer

Res

WW

150 

NA

NA

NASDAQ Initial Public Offerings (IPOs) in oncology

Company

Ticker

Lead product

Technology

Stage

Amount m$

Price $

Genelux

GNLX

Olvi-Vec

Non-pathogenic ntraperitoneal oncolytic vaccinia virus against ovarian cancer

Phase 2

100.0

20

Sdílet na sociálních sítích

Sdílet na sociálních sítích

Vytisknout

Kopírovat odkaz